**Case Report**

**Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma**

Kyotaro Fukuta,1 Hirofumi Izaki,1 Keito Shiozaki,1 Ryoichi Nakanishi,1 Tohru Inai,1 Hideyuki Kataoka,2 Eiji Kudo3 and Kazuya Kanda1

Departments of, 1Urology, 2General Medicine, and 3Pathology, Tokushima Prefectural Central Hospital, Tokushima, Japan

**Introduction:** The nested variant of urothelial carcinoma is rare and shows poor prognosis. We report a case of complete response to pembrolizumab in recurrent nested variant.

**Case presentation:** A 50-year-old man visited another hospital with hematuria and weight loss. Clinical stage T4aN0M0 bladder cancer and acute renal failure were diagnosed. He was referred to our hospital and underwent radical cystectomy. Histological examination showed pathological stage T4aN2 nested variant of urothelial carcinoma. He received 3 cycles of gemcitabine and carboplatin adjuvant chemotherapy. However, para-aortic lymph node metastasis appeared 7 months after cystectomy. He received pembrolizumab as systemic chemotherapy. After 10 cycles, the lesion remained undetectable and we evaluated the response as complete. He has received 18 cycles in total and no recurrences or metastases have been observed.

**Conclusion:** Pembrolizumab may offer effective treatment for nested variant of urothelial carcinoma.

**Key words:** bladder cancer, immunohistochemical staining, nested variant, pembrolizumab, urothelial carcinoma.

**Keynote message**

The nested variant of urothelial carcinoma (NVUC) is an important and rare subtype with poor prognosis. This report describes a complete response to pembrolizumab in recurrent NVUC. Pembrolizumab may be effective for NVUC and immunohistochemical staining for cluster of differentiation-8-positive tumor-infiltrating lymphocytes (CD8+TILs) may help predict response to pembrolizumab.
7.01 mg/dL; eGFR, 7.51 mL/min/1.73 m²). Clinical stage T4aN0M0 bladder cancer and acute postrenal failure due to the mass were diagnosed. TURBT for diagnosis and left percutaneous nephrostomy were performed. Histopathology findings showed invasive UC, high-grade, T2. Therefore, the patient was referred to our hospital for cystectomy. Renal failure did not improve sufficiently despite nephrostomy, so we performed robotic radical cystectomy and ileal conduit without neoadjuvant chemotherapy in February 2019. Histological examination showed high-grade NVUC, T4a (Fig. 2a), and lymph nodes
metastases (pathological stage N2). The nested variant represented more than 90% of the tumor. Since renal failure gradually improved after cystectomy (creatinine, 1.39 mg/dL; eGFR, 44.03 mL/min/1.73 m²), he received adjuvant chemotherapy with gemcitabine (1000 mg/m²) and carboplatin (area under the concentration–time curve, 4) for 3 cycles. However, para-aortic lymph node metastasis appeared 7 months after cystectomy on CT and FDG PET/CT (Fig. 3a). He received pembrolizumab (200 mg) as systemic chemotherapy. After 5 cycles of pembrolizumab therapy, the metastatic lesion (yellow arrow) had decreased in size (Fig. 3b). After 10 cycles, the lesion remained undetectable on CT (yellow arrow). We evaluated the complete response by RECIST version 1.1.

**Discussion**

NVUC, a rare variant of UC, shows an aggressive clinical course. It has been associated with muscle invasion on TURBT, extravesical invasion on radical cystectomy, and metastatic disease compared with pure UC. Holmång et al. reported that 7 of 10 patients who were treated with locoregional therapy died of disease or complications of therapy, 4–40 months after diagnosis. For locally advanced NVUC, radical cystectomy is the best choice, but the treatment strategy has yet to be established because of the rarity of this entity and the lack of randomized studies. Response to neoadjuvant chemotherapy was poor, at only 13%. Adjuvant chemotherapy and radiotherapy have not been shown to be significantly beneficial in reported cases. The present case also represented locally advanced bladder cancer at initial diagnosis. The reason histological examination of the specimen from the initial TURBT did not diagnose NVUC was that they are not enough of the specimen for detecting muscle-invasive UC. Early diagnosis is important, but to diagnose NVUC is difficult from specific findings on urine cytology and cystoscopy remain lacking.

The PD-1 inhibitor pembrolizumab as second-line treatment for advanced/metastatic UC provides benefit in terms of overall survival and safety compared to chemotherapy according to the overall results of the KEYNOTE-045 study. According to that study, pembrolizumab was associated with a benefit over chemotherapy in all the subgroups examined. The present case was in the following subgroups: current smoker; variant histology; and only lymph node metastasis.

---

**Fig. 3** Findings from postoperative abdominal CT and FDG PET/CT. (a, b) Abdominal CT and FDG PET/CT show para-aortic lymph node metastasis (yellow arrow) appearing 7 months after cystectomy. Increased accumulation (SUVmax 2.4, yellow arrow) is seen in the lesion on FDG PET/CT. (c) After 5 cycles of pembrolizumab therapy, the metastatic lesion (yellow arrow) had decreased in size. (d) After 10 cycles, the lesion remained undetectable on CT (yellow arrow). We evaluated the complete response by RECIST version 1.1.

**Fig. 4** Clinical treatment course. He continues to receive pembrolizumab therapy even now.
Pembrolizumab therapy may be effective and safe for patients not fit for cisplatin. The duration of pembrolizumab therapy after complete response is uncertain. Y Fradet, et al. reported that median duration of response to pembrolizumab was not reached (range 1.6 to 30.0 months) on 57 patients who had evaluated complete or partial response. Therefore, we consider to continue pembrolizumab even he has remained in complete response until duration of pembrolizumab therapy is clear.

According to previous reports, the presence of CD8-TILs has been associated with favorable prognosis in colorectal cancer and urothelial cancer. Furthermore, another report indicated that expression of PD-L1 and CD8-TILs is a predictor for response of some solid tumors to PD-1 blockade therapy. We also performed PD-L1, CD8, CD3, CD4, PD-1, Cytokeratin 5/6, GATA3, and p63 immunohistochemical staining of specimens from cystectomy (Fig. 2b–i). All of the expression was positive. Especially we found significant numbers of CD8-positive lymphocytes in the tumor nests, otherwise PD-L1 expression of the tumor cells was low (tumor proportion score nearly 1%). In the KEYNOTE-045 trial, pembrolizumab for advanced UC resulted in significantly improved overall survival regardless of tumor PD-L1 expression status. Fumet et al. reported that CD8 expression was associated with good prognosis in PD-1 blockade therapy for non-small cell lung cancer. CD8 is an important marker of cytotoxic T cells, with effective functioning of CD8-positive T lymphocytes as the main antitumor effector. In the present case, the high density of CD8-TILs might have contributed to response to pembrolizumab.

No previous reports appear to have described the efficacy of pembrolizumab for NVUC. To the best of our knowledge, this may be the first description of complete response to pembrolizumab in recurrent NVUC. Confirming the presence of CD8-TILs may predict the efficacy of pembrolizumab therapy.

Conclusion

We encountered a case of recurrent NVUC with complete response to pembrolizumab. A high density of CD8-TILs may help predict response to pembrolizumab therapy.

Conflict of interest

The authors declare no conflict of interest.

Approval of the research protocol by an institutional reviewer board

Not applicable.

Informed consent

Obtained from the patient.

Registry and the registration no. of the study/trial

Not applicable.

References

1 Holmång S, Johansson SL. The nested variant of transitional cell carcinoma: a rare neoplasm with poor prognosis. Scand. J. Urol. Nephrol. 2001; 35: 102–5.
2 Wasco MJ, Daignault S, Bradley D, Shah RB. Nests variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. Hum. Pathol. 2010; 41: 163–71.
3 Bellmunt J, de Wit R, Vaughn DJ et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 2017; 376: 1015–26.
4 Linder BJ, Frank I, Cheville JC et al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J. Urol. 2013; 189: 1670–5.
5 Xiao GQ, Savage SJ, Gribetz ME, Barstein DE, Miller LK, Unger PD. The nested variant of urothelial carcinoma. Clinicopathology of 2 cases. Arch. Pathol. Lab. Med. 2003; 127: 333–6.
6 Venyo AK. Nested variant of urothelial carcinoma. Adv. Urol. 2014; 2014: 1–24.
7 Fradet Y, Bellmunt J, Vaughn DJ et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann. Oncol. 2019, 30: 970–6.
8 Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005; 353: 2654–66.
9 Sharma P, Shen Y, Wen S et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl Acad. Sci. USA 2007; 104: 3967–72.
10 Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 2007; 7: 10–5.
11 Faraj SF, Munari E, Guner G et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology 2015; 85: 703.e1–6.
12 Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568–71.
13 Fumet J-D, Richard C, Ledys F et al. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br. J. Cancer 2018; 119: 950–60.